Overview

Patient Tolerability Study of GSK163090

Status:
Completed

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of a new drug, GSK163090, which is being developed for the treatment of depression and anxiety disorders.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline